What is the share price of Tatva Chintan Pharma Chem Ltd (TATVA) today?
The share price of TATVA as on 27th July 2026 is ₹1757.30. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Tatva Chintan Pharma Chem Ltd (TATVA) share?
The past returns of Tatva Chintan Pharma Chem Ltd (TATVA) share are- Past 1 week: 20.96%
- Past 1 month: 44.51%
- Past 3 months: 35.63%
- Past 6 months: 53.98%
- Past 1 year: 69.62%
- Past 3 years: 2.58%
- Past 5 years: -25.51%
What are the peers or stocks similar to Tatva Chintan Pharma Chem Ltd (TATVA)?
The peers or stocks similar to Tatva Chintan Pharma Chem Ltd (TATVA) include:What is the dividend yield % of Tatva Chintan Pharma Chem Ltd (TATVA) share?
The current dividend yield of Tatva Chintan Pharma Chem Ltd (TATVA) is 0.12.What is the market cap of Tatva Chintan Pharma Chem Ltd (TATVA) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Tatva Chintan Pharma Chem Ltd (TATVA) is ₹4029.05 Cr as of 27th July 2026.What is the 52 week high and low of Tatva Chintan Pharma Chem Ltd (TATVA) share?
The 52-week high of Tatva Chintan Pharma Chem Ltd (TATVA) is ₹1785 and the 52-week low is ₹976.40.What is the PE and PB ratio of Tatva Chintan Pharma Chem Ltd (TATVA) stock?
The P/E (price-to-earnings) ratio of Tatva Chintan Pharma Chem Ltd (TATVA) is 95.82. The P/B (price-to-book) ratio is 5.45.Which sector does Tatva Chintan Pharma Chem Ltd (TATVA) belong to?
Tatva Chintan Pharma Chem Ltd (TATVA) belongs to the Materials sector & Specialty Chemicals sub-sector.How to buy Tatva Chintan Pharma Chem Ltd (TATVA) shares?
You can directly buy Tatva Chintan Pharma Chem Ltd (TATVA) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Tatva Chintan Pharma Chem Ltd
TATVA Share Price
NSE₹1,757.302.03% (+34.90)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
TATVA Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
BadThe stock is overpriced and in the overbought zone
Red flags
AvgThe stock has a moderate number of red flags
How to use scorecard? Learn more
TATVA Performance & Key Metrics
TATVA Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 78.42 | 5.45 | 0.12% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 23.95 | 3.15 | 1.41% |
67%
Analysts have suggested that investors can buy this stock
from 3 analysts
Price Upside
Earnings Growth
Rev. Growth
TATVA Company Profile
Tatva Chintan Pharma Chem is engaged in the manufacturing business of chemical products.
FLUOROCHEM
PE Ratio
87.53
87.53
1Y Return
27.89%
27.89%
Buy Reco %
73.33
73.33
NAVINFLUOR
PE Ratio
58.14
58.14
1Y Return
48.10%
48.10%
Buy Reco %
77.78
77.78
AETHER
PE Ratio
86.33
86.33
1Y Return
76.67%
76.67%
Buy Reco %
60.00
60.00
AARTIIND
PE Ratio
41.36
41.36
1Y Return
10.17%
10.17%
Buy Reco %
83.33
83.33
FINEORG
PE Ratio
35.49
35.49
1Y Return
10.35%
10.35%
Buy Reco %
80.00
80.00
TATVA Sentiment Analysis
TATVA Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
TATVA Stock Summary · May 2026
Margin-driven progress amid modest sequential revenue growth was the dominant message, with operating revenue of INR 1,341 million in Q4 and EBITDA of INR 281 million (around a 21% margin) underscoring profitability gains tied to mix and operating leverage. Management emphasized commercialising higher‑value lines—notably an outsized recovery in electrolyte salts and strong SDA demand ahead of Euro 7—while bringing a new Dahej block to commercial scale (80%–85% current utilisation with a target margin near 25% at full ramp) and initiating the Jolva greenfield project with phased capex and an 18–20 month build timeline. They acknowledged tension between cost inflation—some inputs rising roughly 30%–40%—and largely successful price pass‑throughs, plus a short amine disruption that has since normalized; heavy capex also inflated the quarter’s effective tax rate (~38%) through deferred tax impacts. For the near term management reiterated FY27 targets of roughly 25% revenue growth and a blended EBITDA margin of 20%–22%, with electrolyte salts expected to account for about 8%–10% of revenues.
TATVA Stock Growth Drivers
TATVA Stock Growth Drivers
6Robust recent financial performance and annual revenue milestone
The company delivered a strong Q4 FY26 operating performance with revenue of INR 1,341 million
Capacity expansion and structured greenfield pipeline (Dahej ramp‑up and Jolva)
The manufacturing footprint has expanded and is being purposefully scaled: a new production block at
TATVA Stock Challenges
TATVA Stock Challenges
6Rising input costs and intermittent supply disruptions
Geopolitical conflicts and commodity volatility have already driven material input-cost pressure and produced intermittent supply
Operational setbacks from new-facility commissioning
The transition of production into a new facility caused tangible, realized operational setbacks that reduced
TATVA Forecast
TATVA Forecasts
Price
Revenue
Earnings
TATVA Share Price Forecast
TATVA Share Price Forecast
2026
Current
₹1,722.40
Baseline
Forecast for Jul 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
2026
Current
₹1,722.40
Baseline
Forecast for Jul 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
TATVA Company Revenue Forecast
TATVA Company Revenue Forecast
2026
Current
₹509.41
Baseline
Forecast for Mar 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹ cr.
2026
Current
₹509.41
Baseline
Forecast for Mar 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹ cr.
TATVA Stock EPS (Earnings Per Share) Forecast
TATVA Stock EPS (Earnings Per Share) Forecast
2026
Current
₹17.98
Baseline
Forecast for Mar 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
2026
Current
₹17.98
Baseline
Forecast for Mar 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
TATVA
TATVA
Income
Balance Sheet
Cash Flow
Quarterly Normal View
TATVA Income Statement
TATVA Income Statement
Quarterly Normal View
| Quarter | mar 2024 | jun 2024 | sep 2024 | dec 2024 | mar 2025 | jun 2025 | sep 2025 | dec 2025 | mar 2026 | jun 2026 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 102.79 | 106.64 | 83.87 | 85.94 | 108.59 | 118.02 | 124.52 | 133.07 | 133.80 | 169.84 | ||||||||||
Operating & Other expenses | 82.66 | 92.85 | 77.90 | 78.84 | 98.91 | 99.53 | 101.30 | 105.85 | 106.02 | 136.08 | ||||||||||
EBITDA | 20.13 | 13.79 | 5.97 | 7.10 | 9.68 | 18.49 | 23.22 | 27.22 | 27.78 | 33.76 | ||||||||||
| Depreciation/Amortization | 6.23 | 6.67 | 6.81 | 6.92 | 7.26 | 8.97 | 9.05 | 9.07 | 9.76 | 10.57 | ||||||||||
| PBIT | 13.90 | 7.12 | -0.84 | 0.18 | 2.42 | 9.52 | 14.17 | 18.15 | 18.02 | 23.19 | ||||||||||
| Interest & Other Items | 0.21 | 0.31 | 0.17 | 0.42 | 0.39 | 0.41 | 0.51 | 0.49 | 1.44 | 2.08 | ||||||||||
| PBT | 13.69 | 6.81 | -1.01 | -0.24 | 2.03 | 9.11 | 13.66 | 17.66 | 16.58 | 21.11 | ||||||||||
| Taxes & Other Items | 4.07 | 1.60 | -0.35 | -0.38 | 1.00 | 2.45 | 3.75 | 2.49 | 6.26 | 5.13 | ||||||||||
| Net Income | 9.62 | 5.21 | -0.66 | 0.14 | 1.03 | 6.66 | 9.91 | 15.17 | 10.32 | 15.98 | ||||||||||
| EPS | 4.11 | 2.23 | -0.29 | 0.06 | 0.44 | 2.84 | 4.24 | 6.49 | 4.41 | 6.83 |
TATVA Company Updates
FY 2027FY 2027
Investor Presentation
Jul 17PDF
FY 2026FY 2026
Investor Presentation
May 16PDF
Jan 21PDF
Oct 31PDF
Jul 24PDF
TATVA Stock Peers
TATVA Past Performance & Peer Comparison
TATVA Past Performance & Peer Comparison
Comparing 3 stocks from
MaterialsSpecialty Chemicals
Compare valuation on Screener
MaterialsSpecialty Chemicals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Tatva Chintan Pharma Chem Ltd | 95.82 | 5.45 | 0.12% |
| Gujarat Fluorochemicals Ltd | 87.53 | 6.88 | 0.07% |
| Navin Fluorine International Ltd | 58.14 | 9.71 | 0.11% |
| Aether Industries Ltd | 86.33 | 8.51 | — |
TATVA Stock Price Comparison
Compare TATVA with any stock or ETFCompare TATVA with any stock or ETF
TATVA
TATVA Holdings
TATVA Shareholdings
TATVA Promoter Holdings Trend
TATVA Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
TATVA Institutional Holdings Trend
TATVA Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
TATVA Shareholding Pattern
TATVA Shareholding Pattern
TATVA Shareholding History
TATVA Shareholding History
Foreign Institutions
Mutual Funds Invested in TATVA
Mutual Funds Invested in TATVA
No mutual funds holding trends are available
Top 5 Mutual Funds holding Tatva Chintan Pharma Chem Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 1.5316% | Percentage of the fund’s portfolio invested in the stock 0.41% | Change in the portfolio weight of the stock over the last 3 months -0.01% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 65/72 (-1) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.1989% | Percentage of the fund’s portfolio invested in the stock 0.46% | Change in the portfolio weight of the stock over the last 3 months -0.00% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 52/61 (-4) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.1682% | Percentage of the fund’s portfolio invested in the stock 0.17% | Change in the portfolio weight of the stock over the last 3 months -0.00% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 45/56 (-2) |
Compare 3-month MF holding change on Screener
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases containing TATVA stock
smallcases containing TATVA stock
Looks like this stock is not in any smallcase yet.
TATVA Events
TATVA Events
TATVA Dividend Trend
No Trend In Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
TATVA has shown inconsistent dividend trend over the last 5 years
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 0.12%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹1.16 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
TATVA Dividend Trend
No Trend In Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
TATVA has shown inconsistent dividend trend over the last 5 years
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 0.12%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹1.16 every year
TATVA Upcoming Dividends
TATVA Upcoming Dividends
No upcoming dividends are available
TATVA Past Dividends
TATVA Past Dividends
Cash Dividend
Ex DateEx DateSep 12, 2025
Final
Final | Div/Share: ₹1.00
Dividend/Share
₹1.00
Ex DateEx Date
Sep 12, 2025
Cash Dividend
Ex DateEx DateSep 6, 2024
Final
Final | Div/Share: ₹2.00
Dividend/Share
₹2.00
Ex DateEx Date
Sep 6, 2024
Cash Dividend
Ex DateEx DateSep 8, 2023
Final
Final | Div/Share: ₹2.00
Dividend/Share
₹2.00
Ex DateEx Date
Sep 8, 2023
Cash Dividend
Ex DateEx DateSep 8, 2022
Final
Final | Div/Share: ₹2.00
Dividend/Share
₹2.00
Ex DateEx Date
Sep 8, 2022
TATVA Stock News & Opinions
TATVA Stock News & Opinions
Articles & Videos
Corporate
Corporate
Tatva Chintan Pharma Chem commences construction of greenfield unit at DahejTatva Chintan Pharma Chem held the Groundbreaking Ceremony (Bhoomi Pujan) at the new greenfield unit at Dahej - III, Dahej Industrial Estate, Taluka: Vagra, District: Bharuch, Gujarat, India on 20 July 2026.
5 days agoCapital Market - Live
Spotlight
Spotlight
Tatva Chintan Pharma Chem Ltd leads gainers in 'B' groupShalimar Paints Ltd, Ashima Ltd, Bhansali Engineering Polymers Ltd and Kross Ltd are among the other gainers in the BSE's 'B' group today, 20 July 2026.Tatva Chintan Pharma Chem Ltd surged 19.32% to Rs 1704.45 at 12:01 IST. The stock was the biggest gainer in the BSE's 'B' group. On the BSE, 1.99 lakh shares were traded on the counter so far as against the average daily volumes of 3568 shares in the past one month. Shalimar Paints Ltd soared 15.64% to Rs 57. The stock was the second biggest gainer in 'B' group. On the BSE, 20704 shares were traded on the counter so far as against the average daily volumes of 6276 shares in the past one month. Ashima Ltd spiked 13.75% to Rs 16.38. The stock was the third biggest gainer in 'B' group. On the BSE, 1.35 lakh shares were traded on the counter so far as against the average daily volumes of 11700 shares in the past one month. Bhansali Engineering Polymers Ltd jumped 13.03% to Rs 127.3. The stock was the fourth biggest gainer in 'B' group. On the BSE, 29.9 lakh shares were traded on the counter so far as against the average daily volumes of 56776 shares in the past one month. Kross Ltd spurt 11.14% to Rs 214. The stock was the fifth biggest gainer in 'B' group. On the BSE, 7.83 lakh shares were traded on the counter so far as against the average daily volumes of 17518 shares in the past one month. Powered by Capital Market - Live
1 week agoCapital Market - Live
Spotlight
Spotlight
Tatva Chintan Pharma rallies after Q1 PAT jumps more than two-foldThe company's consolidated net profit soared 140.3% to Rs 15.98 crore in Q1 FY27, compared with Rs 6.65 crore in Q1 FY26. Revenue from operations jumped 42.95% YoY to Rs 167.05 crore in the quarter ended 30th June 2026. Profit before exceptional items and tax (PBT) increased 118.58% to Rs 15.41 crore in Q1 FY27 from Rs 7.05 crore in Q1 FY26. The company reported exceptional items of Rs 1.31 crore during the quarter. EBITDA climbed 86% YoY to Rs 32.3 crore in Q1 FY27 from Rs 17.3 crore in the year-ago period. EBITDA margin improved to 19% from 15%, reflecting stronger operating performance. During the quarter, Pharmaceuticals and Agrochemicals Intermediates and other Specialty Chemicals (PASC) contributed 35% of total revenue, followed by Structure Directing Agents (SDA) at 34%, Phase Transfer Catalysts (PTC) at 26%, Electrolyte Salts & Solutions (ESS) at 4%, while the remaining 1% came from other products. Segment-wise, revenue from PASC stood at Rs 58.4 crore, SDA at Rs 57.8 crore, PTC at Rs 42.8 crore and ESS at Rs 6.3 crore during the period under review. Tatva Chintan Pharma Chem is primarily engaged in manufacturing, sale and distribution of specialty chemicals, viz., phase transfer catalysts (PTC), structure directing agents (SDA), electrolyte salts and solutions (ESS), pharmaceutical and agrochemical intermediates and other specialty chemicals (PASC).Powered by Capital Market - Live
1 week agoCapital Market - Live
Earnings
Earnings
Tatva Chintan Pharma Chem consolidated net profit rises 140.30% in the June 2026 quarterNet profit of Tatva Chintan Pharma Chem rose 140.30% to Rs 15.98 crore in the quarter ended June 2026 as against Rs 6.65 crore during the previous quarter ended June 2025. Sales rose 42.96% to Rs 167.06 crore in the quarter ended June 2026 as against Rs 116.86 crore during the previous quarter ended June 2025. ParticularsQuarter EndedJun. 2026Jun. 2025% Var. Sales167.06116.86 43 OPM %19.3314.83 - PBDT33.0018.07 83 PBT22.439.10 146 NP15.986.65 140 Powered by Capital Market - Live
1 week agoCapital Market - Live
Corporate
Corporate
Tatva Chintan Pharma Chem to hold board meetingTatva Chintan Pharma Chem will hold a meeting of the Board of Directors of the Company on 17 July 2026.
2 weeks agoCapital Market - Live
Corporate
Corporate
Board of Tatva Chintan Pharma Chem recommends final dividendTatva Chintan Pharma Chem announced that the Board of Directors of the Company at its meeting held on 16 May 2026, inter alia, have recommended the final dividend of Rs 2 per equity Share (i.e. 20%) , subject to the approval of the shareholders.
2 months agoCapital Market - Live
Earnings
Earnings
Tatva Chintan Pharma Chem consolidated net profit rises 901.94% in the March 2026 quarterNet profit of Tatva Chintan Pharma Chem rose 901.94% to Rs 10.32 crore in the quarter ended March 2026 as against Rs 1.03 crore during the previous quarter ended March 2025. Sales rose 24.36% to Rs 134.14 crore in the quarter ended March 2026 as against Rs 107.86 crore during the previous quarter ended March 2025. For the full year,net profit rose 636.43% to Rs 42.05 crore in the year ended March 2026 as against Rs 5.71 crore during the previous year ended March 2025. Sales rose 32.18% to Rs 505.86 crore in the year ended March 2026 as against Rs 382.71 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales134.14107.86 24 505.86382.71 32 OPM %20.978.30 -18.428.94 - PBDT26.349.29 184 93.8635.24 166 PBT16.592.03 717 57.017.58 652 NP10.321.03 902 42.055.71 636 Powered by Capital Market - Live
2 months agoCapital Market - Live
Earnings
Earnings
Tatva Chintan Pharma Chem standalone net profit rises 720.00% in the March 2026 quarterNet profit of Tatva Chintan Pharma Chem rose 720.00% to Rs 9.02 crore in the quarter ended March 2026 as against Rs 1.10 crore during the previous quarter ended March 2025. Sales rose 23.24% to Rs 132.67 crore in the quarter ended March 2026 as against Rs 107.65 crore during the previous quarter ended March 2025. For the full year,net profit rose 11742.42% to Rs 39.08 crore in the year ended March 2026 as against Rs 0.33 crore during the previous year ended March 2025. Sales rose 35.45% to Rs 496.30 crore in the year ended March 2026 as against Rs 366.42 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales132.67107.65 23 496.30366.42 35 OPM %20.007.35 -18.007.05 - PBDT24.728.82 180 90.0128.11 220 PBT14.971.56 860 53.170.46 11459 NP9.021.10 720 39.080.33 11742 Powered by Capital Market - Live
2 months agoCapital Market - Live
Corporate
Corporate
Tatva Chintan Pharma Chem to conduct board meetingTatva Chintan Pharma Chem will hold a meeting of the Board of Directors of the Company on 16 May 2026.
2 months agoCapital Market - Live
Earnings
Earnings
Tatva Chintan Pharma Chem consolidated net profit rises 10735.71% in the December 2025 quarterNet profit of Tatva Chintan Pharma Chem rose 10735.71% to Rs 15.17 crore in the quarter ended December 2025 as against Rs 0.14 crore during the previous quarter ended December 2024. Sales rose 52.89% to Rs 131.33 crore in the quarter ended December 2025 as against Rs 85.90 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales131.3385.90 53 OPM %19.418.22 - PBDT26.736.69 300 PBT17.66-0.24 LP NP15.170.14 10736 Powered by Capital Market - Live
6 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 10.76%, vs industry avg of 13.78%
Over the last 5 years, market share decreased from 0.5% to 0.41%
Over the last 5 years, net income has grown at a yearly rate of -4.26%, vs industry avg of 19.4%